Innovating Second Generation Antibodies Targeting Toxic Proteinopathies with Enhanced Blood-Brain Barrier Penetrance
Time: 3:30 pm
day: Conference Day Two PM
Details:
- Reviewing the latest progress of shuttling technologies to enhance therapeutic targeting to the brain and reduce side effects like ARIA
- Investigating mechanisms of transport across the BBB to uncover opportunities to more effectively target neurodegenerative protein aggregates
- Widening the cargo space of antibody brain shuttles; what other modalities can be applied?
